Moffitt Cancer Center | Strategic Alliance Partners
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 53 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 7,800 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
Latest from Moffitt Cancer Center
OncLive’s FDA Approval Report: The Regulatory Rundown for March 2025
April 02, 2025
Article
Here is your snapshot for all therapeutic options that were approved by the FDA in March 2025 spanning tumor types.
Moffitt Study Finds New Immunotherapy Strategy for Enhancing Melanoma Treatment
March 24, 2025
Article
Moffitt Cancer Center researchers found a way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure.
PARP Inhibitor and ARPI Combinations Are at the Forefront of Investigations in mCRPC
March 20, 2025
Article
Monica Chatwal, MD, details new research shedding light on PARP/ARPI combinations in mCRPC, especially in BRCA-mutated and HRR gene–altered populations.
Dr Chiappori on the Integration of Ensartinib Into the NSCLC Treatment Arsenal
March 11, 2025
Video
Alberto Chiappori, MD, discusses the selection between frontline treatment options, including ensartinib, in ALK-positive non–small cell lung cancer.
Moffitt Study Identifies Immune Response That May Stop Breast Cancer from Spreading
March 11, 2025
Article
A new Moffitt Cancer Center study has identified a specific immune response that may prevent the spread of breast cancer cells within the body.
Ensartinib Looks to Find a Place in ALK+ NSCLC Paradigm Alongside Approved TKIs
March 05, 2025
Article
Alberto Chiappori, MD, details how to select between ensartinib and approved ALK TKIs for NSCLC, as well as considerations with ensartinib’s FDA approval.
Highlighting Key CML/ALL Data Presented at ASH 2024
January 23, 2025
Video
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, highlight key data in CML and ALL presented at the 2024 ASH Annual Meeting.
Selecting a TKI in Subsequent Lines of Therapy in CML
January 23, 2025
Video
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, detail factors for selecting a TKI in later lines of therapy in chronic myeloid leukemia.
The Role of Frontline Ponatinib Plus Chemo in Ph+ ALL
January 23, 2025
Video
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss data for ponatinib plus chemotherapy in Ph-positive ALL.
Dosing Strategies for Ponatinib in CML and ALL
January 23, 2025
Video
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss dosing strategies for ponatinib in CML and ALL.
Emerging Mutation Analysis from the OPTIC Trial
January 23, 2025
Video
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the mutational analysis for ponatinib in the OPTIC trial in CP-CML.
5-year Data for Ponatinib in Pretreated CP-CML from the OPTIC Trial
January 23, 2025
Video
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss 5-year data for ponatinib in pretreated CP-CML.
Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD
December 24, 2024
Podcast
Drs Chan and Hunter discuss asciminib in first-line CML, OPTIC trial data on ponatinib dosing, mutational testing, and stem cell transplant strategies.
Factors That Influence Treatment Decisions in Later-Line CML
December 18, 2024
Video
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Implications of the FDA Approval of Asciminib for Newly Diagnosed, Ph+ CP-CML
December 18, 2024
Video
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Dr Kuykendall on the Advantages of Treatment With Momelotinib in Myelofibrosis
December 10, 2024
Video
Andrew Kuykendall, MD, discusses the advantages of treatment with momelotinib vs older-generation JAK inhibitors in myelofibrosis.
Highlights in MPNs, CLL With Drs Prithviraj Bose and Javier Pinilla Ibarz
December 09, 2024
Video
Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, and Javier Pinilla Ibarz, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest in myeloproliferative neoplasms and chronic lymphocytic leukemia, respectively, from the 2024 ASH Annual Meeting.
Moffitt Study Shows How Cancer Cell Death May Harm the Immune System and Promote Tumor Growth
December 02, 2024
Article
Researchers at Moffitt Cancer Center published an article in Cancer Cell showing that necroptosis-mediated immune suppression occurs through release of IL-1α.
Dr Forsyth on a Phase 1 Study Evaluating Intrathecal cDC1s in Leptomeningeal Disease
November 20, 2024
Video
Peter Forsyth, MD, discusses the design of a first-in-human phase 1 trial evaluating HER2/HER3–targeted intrathecal dendritic cells in leptomeningeal disease.
Dr Kim on the CARES-310 Study of Rivoceranib Plus Camrelizumab in First-Line HCC
November 19, 2024
Video
Richard Kim, MD, discusses the phase 3 CARES-310 trial evaluating rivoceranib plus camrelizumab in first-line hepatocellular carcinoma.